Tg Therapeutics (TGTX) Total Non-Current Liabilities (2010 - 2026)
Tg Therapeutics (TGTX) posted quarterly Total Non-Current Liabilities of $944.9 million for Q1 2026, up 126.47% year-over-year from $417.2 million in Q1 2025, and up 128.72% quarter-over-quarter from $413.1 million in Q4 2025.
Tg Therapeutics (TGTX) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Tg Therapeutics' Total Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $944.9 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 126.47% year-over-year to $944.9 million; the TTM figure through Mar 2026 stood at $944.9 million (up 126.47% YoY), while the FY2025 annual figure was $413.1 million, up 17.52% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $944.9 million, up from $413.1 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $944.9 million in Q1 2026, with the low at $134.7 million in Q4 2022.
- The 5-year median for Total Non-Current Liabilities is $390.8 million (2024), against an average of $372.0 million.
- The sharpest annual moves came in 2022 and 2026: Total Non-Current Liabilities dropped 5.19% in 2022, then surged 126.47% in 2026.
- Tg Therapeutics' Total Non-Current Liabilities stood at $134.7 million in 2022, then grew by 25.22% to $168.7 million in 2023, then jumped by 108.34% to $351.5 million in 2024, then climbed by 17.52% to $413.1 million in 2025, then soared by 128.72% to $944.9 million in 2026.
- Business Quant data shows TGTX's Total Non-Current Liabilities at $944.9 million in Q1 2026, $413.1 million in Q4 2025, and $415.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn | 1.03 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.03 Bn |
| Mar 31, 2026 | 944.93 Mn |
| Dec 31, 2025 | 413.13 Mn |
| Sep 30, 2025 | 415.84 Mn |
| Jun 30, 2025 | 423.97 Mn |
| Mar 31, 2025 | 417.24 Mn |
| Dec 31, 2024 | 351.54 Mn |
| Sep 30, 2024 | 390.78 Mn |
| Jun 30, 2024 | 220.56 Mn |
| Mar 31, 2024 | 210.42 Mn |
| Dec 31, 2023 | 168.73 Mn |
| Dec 31, 2022 | 134.74 Mn |
| Dec 31, 2021 | 142.12 Mn |
| Sep 30, 2021 | 97.55 Mn |
| Jun 30, 2021 | 97.55 Mn |
| Mar 31, 2021 | 102.53 Mn |
| Dec 31, 2020 | 105.35 Mn |
| Sep 30, 2020 | 102.72 Mn |
| Jun 30, 2020 | 100.05 Mn |
| Mar 31, 2020 | 103.03 Mn |